Longitudinal data from naturally occurring cancer.
Longitudinal data from naturally occurring cancer.
Longitudinal data from naturally occurring cancer.
Clyra combines human cancer data with molecular, treatment, and outcome data collected over the course of naturally occurring cancers in dogs. Each dataset is interpreted within its own species, cohort, and clinical context.
Clyra combines human cancer data with molecular, treatment, and outcome data collected over the course of naturally occurring cancers in dogs. Each dataset is interpreted within its own species, cohort, and clinical context.
Human cancer data
Human cancer data
Human cancer datasets provide the primary clinical and biological context for human oncology research. Depending on the program, relevant data may include tumor molecular profiles, clinical annotations, treatment exposure, response, progression, and survival.
Human cancer datasets provide the primary clinical and biological context for human oncology research. Depending on the program, relevant data may include tumor molecular profiles, clinical annotations, treatment exposure, response, progression, and survival.
Human evidence remains necessary for evaluating the relevance of any cross-species finding.
Human evidence remains necessary for evaluating the relevance of any cross-species finding.
Canine cancer data
Canine cancer data
Dogs develop cancer naturally in the presence of an intact immune system and receive treatment in clinical care. Their disease course can make it possible to observe molecular profiles, treatment exposure, progression, recurrence, and outcomes over a practical period.
Dogs develop cancer naturally in the presence of an intact immune system and receive treatment in clinical care. Their disease course can make it possible to observe molecular profiles, treatment exposure, progression, recurrence, and outcomes over a practical period.
Clyra uses these longitudinal trajectories as a complementary source of cancer biology. The platform does not treat canine cancer as a substitute for human cancer or assume that every biological signal transfers across species.
Clyra uses these longitudinal trajectories as a complementary source of cancer biology. The platform does not treat canine cancer as a substitute for human cancer or assume that every biological signal transfers across species.
Molecular context
Genomic, transcriptomic, epigenetic, cellular, or other molecular data when available.
Treatment context
Therapy, timing, sequencing, dose, and relevant clinical annotations when available.
Longitudinal outcomes
Response, progression, recurrence, survival, and repeated measurements when available.
Cross-species alignment
Cross-species alignment
Cross-species analysis requires more than combining records in one dataset. Gene homology, pathway conservation, tumor composition, clinical endpoints, cohort structure, and species-specific effects must be represented explicitly. Clyra’s modeling approach is designed to identify both conserved and species-specific patterns, with human relevance evaluated using human data.
Cross-species analysis requires more than combining records in one dataset. Gene homology, pathway conservation, tumor composition, clinical endpoints, cohort structure, and species-specific effects must be represented explicitly. Clyra’s modeling approach is designed to identify both conserved and species-specific patterns, with human relevance evaluated using human data.
Data quality and provenance
Data quality and provenance
Dataset provenance, collection methods, endpoint definitions, missingness, treatment context, and batch effects should remain visible throughout an analysis. These factors are considered in model development and evaluation rather than removed from the biological context.
Dataset provenance, collection methods, endpoint definitions, missingness, treatment context, and batch effects should remain visible throughout an analysis. These factors are considered in model development and evaluation rather than removed from the biological context.